YH-12852 is under clinical development by Yuhan and currently in the Phase I and Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect YH-12852’s likelihood of approval (LoA) and phase transition for Diabetic Gastroparesis took place on 15 Nov 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

In addition, the same event on 15 Nov 2022 increased YH-12852’s LoA and PTSR for Gastroparesis.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their YH-12852 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

YH-12852 overview

YH-12852 is under development for the treatment of chronic constipation, postoperative ileus, gastroparesis and diabetic gastroparesis. The drug candidate is a new chemical entity administered through the oral route. It acts by targeting 5-HT receptor. It was also under development for irritable bowel syndrome (IBS), functional dyspepsia and chronic constipation.

Yuhan overview

Yuhan discovers, develops, manufactures and markets pharmaceutical products. The company offers APIs and intermediates for antibiotic, antiviral, antifungal, anti-thrombotic, anti-inflammatory, anti-diabetic, and anti-hyperlipidemics. The company offers finished goods for the treatment of hypertension, coronary artery disease, hyperlipidemia, cerebral thrombosis and other diseases. Yuhan provides custom synthesis services for other pharmaceutical and biopharmaceutical companies. It offers active pharmaceutical ingredients (API) and finished products in domestic as well as international market. Yuhan operates R&D and manufacturing facilities in Seoul. The company offers its products and services through its sales and distribution branches. Yuhan is headquartered in Seoul, South Korea.

Quick View YH-12852 LOA Data

Report Segments
  • Innovator
Drug Name
  • YH-12852
Administration Pathway
  • Oral
Therapeutic Areas
  • Gastrointestinal
  • Toxicology
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.